J A Foekens

Summary

Affiliation: University Hospital Rotterdam
Country: The Netherlands

Publications

  1. pmc Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance
    L Y Luo
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, M5G 1X5, Canada
    Br J Cancer 86:1790-6. 2002
  2. ncbi Prognostic significance of cathepsins B and L in primary human breast cancer
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute, Dr Daniel den Hoed Kliniek Academic Hospital Rotterdam, The Netherlands
    J Clin Oncol 16:1013-21. 1998
  3. ncbi Prognostic value of CD44 variant expression in primary breast cancer
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital, The Netherlands
    Int J Cancer 84:209-15. 1999
  4. ncbi The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer
    John A Foekens
    Erasmus MC Daniel den Hoed, Department of Medical Oncology, 3000 DR Rotterdam, The Netherlands
    Cancer Res 63:337-41. 2003
  5. ncbi The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital, The Netherlands
    Cancer Res 60:636-43. 2000
  6. ncbi Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek, Academic Hospital Rotterdam, The Netherlands
    Cancer Res 61:1421-5. 2001
  7. ncbi High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer
    J A Foekens
    Division of Endocrine Oncology, Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Cancer Res 61:5407-14. 2001
  8. ncbi Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
    E M Berns
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel de Hoed Kliniek University Hospital Rotterdam, The Netherlands
    Cancer Res 60:2155-62. 2000
  9. ncbi p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
    E M Berns
    Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek University Hospital Rotterdam, The Netherlands
    J Clin Oncol 16:121-7. 1998
  10. pmc Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
    J A Foekens
    Department of Medical Oncology, Mount Sinai Hospital, Toronto, Ontario, Canada
    Br J Cancer 79:888-94. 1999

Detail Information

Publications97

  1. pmc Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance
    L Y Luo
    Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, M5G 1X5, Canada
    Br J Cancer 86:1790-6. 2002
    ..Taken together, our results suggest that although human kallikrein 6 and human kallikrein 10 are not prognostic markers for breast cancer, human kallikrein 10 is an independent predictive marker for response of tamoxifen therapy...
  2. ncbi Prognostic significance of cathepsins B and L in primary human breast cancer
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute, Dr Daniel den Hoed Kliniek Academic Hospital Rotterdam, The Netherlands
    J Clin Oncol 16:1013-21. 1998
    ..Evaluation of the clinical significance of cytosolic tumor levels of the lysosomal cysteine proteases cathepsin B (catB) and cathepsin L (catL) in patients with primary breast cancer...
  3. ncbi Prognostic value of CD44 variant expression in primary breast cancer
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital, The Netherlands
    Int J Cancer 84:209-15. 1999
    ..However, the expression of exon v6 of CD44 may be a marker to identify patients with a relatively favorable prognosis in node-negative patients...
  4. ncbi The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer
    John A Foekens
    Erasmus MC Daniel den Hoed, Department of Medical Oncology, 3000 DR Rotterdam, The Netherlands
    Cancer Res 63:337-41. 2003
    ..Our present study suggests that PMN-E is associated with breast cancer metastasis, and knowledge of the tumor PMN-E status might be helpful in selecting the appropriate individualized (adjuvant) treatment for patients with breast cancer...
  5. ncbi The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital, The Netherlands
    Cancer Res 60:636-43. 2000
    ..Knowledge of these factors could be helpful to assess the individual risk of patients, to select various types of adjuvant treatment and to identify patients who may benefit from targeted therapies that are currently being developed...
  6. ncbi Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek, Academic Hospital Rotterdam, The Netherlands
    Cancer Res 61:1421-5. 2001
    ..Elevated tumor TS activity predicts a favorable outcome for 5-FU-containing polychemotherapy when applied after tumor progression on endocrine therapy...
  7. ncbi High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer
    J A Foekens
    Division of Endocrine Oncology, Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Cancer Res 61:5407-14. 2001
    ..Knowledge of the tumor level of VEGF might be helpful in selecting individual patients who may benefit from treatments with antiangiogenic agents combined with conventionally used drugs...
  8. ncbi Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer
    E M Berns
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel de Hoed Kliniek University Hospital Rotterdam, The Netherlands
    Cancer Res 60:2155-62. 2000
    ..The type of mutation and its biological function should be considered in the analyses of the predictive value of TP53...
  9. ncbi p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer
    E M Berns
    Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek University Hospital Rotterdam, The Netherlands
    J Clin Oncol 16:121-7. 1998
    ..We studied whether p53 protein accumulation is a predictive factor for response to tamoxifen treatment in patients with recurrent breast cancer...
  10. pmc Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
    J A Foekens
    Department of Medical Oncology, Mount Sinai Hospital, Toronto, Ontario, Canada
    Br J Cancer 79:888-94. 1999
    ..It is concluded that the level of PSA in cytosols of primary breast tumours might be a marker to select breast cancer patients who may benefit from systemic tamoxifen therapy...
  11. ncbi TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients
    E M Berns
    Department of Medical Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Genes Chromosomes Cancer 16:170-9. 1996
    ..8 and 1.6, respectively, in analysis for relapse-free survival and of 1.7 and 1.6, respectively, in analysis for overall survival...
  12. pmc High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer
    M P H M Jansen
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Center, Erasmus Medical Center Rotterdam, Room Be401, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 133:937-47. 2012
    ..Cell cycle regulation is the only overlapping pathway linked to miR-26a and EZH2 levels. Low mRNA levels of EZH2, CCNE1, and CDC2, and high levels of miR-26a are associated with favorable outcome on tamoxifen...
  13. pmc Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients
    J A Foekens
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, Academic Hospital, The Netherlands
    Br J Cancer 79:300-7. 1999
    ..3 to 1.5, compared with tumours with low cathepsin-D levels. The results presented here on 2810 patients confirm that high cytosolic cathepsin-D values are associated with poor prognosis in human primary breast cancer...
  14. ncbi Uptake and distribution of doxorubicin in hormone-manipulated human breast cancer cells in vitro
    M Bontenbal
    Department of Medical Oncology, Rotterdam Cancer Institute, University Hospital, The Netherlands
    Breast Cancer Res Treat 51:139-48. 1998
    ..In the present study the in vitro effects of estradiol-mediated DNA stimulation on the cellular uptake of the DNA intercalating drug doxorubicin (DOX) were examined in MCF-7 human breast cancer cells...
  15. ncbi High prevalence of codon 213Arg-->Stop mutations of the TP53 gene in human ovarian cancer in the southwestern part of The Netherlands
    M Schuyer
    Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek University Hospital Rotterdam, The Netherlands
    Int J Cancer 76:299-303. 1998
    ..A frequent nonsense mutation at codon 213 in 5 (8%) of 64 tumour specimens represents an important finding...
  16. pmc The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy
    P Manders
    Department of Medical Oncology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Br J Cancer 87:772-8. 2002
    ..This implies that vascular endothelial growth factor is related with the natural course of breast cancer progression...
  17. ncbi Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors
    M E van der Burg
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital, The Netherlands
    Int J Cancer 69:475-9. 1996
    ..After adjustment for FIGO stage/tumor rest, only age retained its prognostic significance, in the analysis for progression-free survival and in that for overall survival...
  18. ncbi Predictive value of SRC-1 for tamoxifen response of recurrent breast cancer
    E M Berns
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek University Hospital Rotterdam, The Netherlands
    Breast Cancer Res Treat 48:87-92. 1998
    ..The median SRC-1 level was, however, lower in tumors from patients that did not respond to tamoxifen. Our findings suggest that high levels of SRC-1 indicate a favorable response to tamoxifen of patients with recurrent breast cancer...
  19. pmc Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer
    E M Berns
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek University Hospital Rotterdam, The Netherlands
    Br J Cancer 77:1130-6. 1998
    ..05) and overall survival (P < 0.02). These data imply that in the analysis of the prognostic value of TP53, the type of mutation and its biological function should be considered...
  20. ncbi Cytokine-regulated urokinase-type-plasminogen-activator (uPA) production by human breast fibroblasts in vitro
    A M Sieuwerts
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital Rotterdam, The Netherlands
    Breast Cancer Res Treat 55:9-20. 1999
    ..Altogether, our data suggest an active role for fibroblasts in the process of uPA-directed breast tumor proteolysis...
  21. pmc Elevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease
    J A Foekens
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, Rotterdam, The Netherlands
    Br J Cancer 88:1084-90. 2003
    ..Our present results suggest that PMN-E is an independent predictive marker for the efficacy of tamoxifen treatment in patients with advanced breast cancer...
  22. ncbi Clinical relevance of biologic factors in male breast cancer
    M E Meijer-van Gelder
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, University Hospital, The Netherlands
    Breast Cancer Res Treat 68:249-60. 2001
    ..Correlation of the eight cell biologic factors with disease outcome showed that PAI-1 (p = 0.03) was the only independent predictive factor for poor prognosis in male breast cancer...
  23. doi Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer
    E A Reijm
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 125:387-94. 2011
    ..High levels of EZH2 are associated with poor outcome to tamoxifen therapy in advanced breast cancer. Downregulated EZH2 leads to upregulation of the ER and better response to anti-estrogens...
  24. ncbi Assessment of the invasive potential of human gynecological tumor cell lines with the in vitro Boyden chamber assay: influences of the ability of cells to migrate through the filter membrane
    A M Sieuwerts
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital, The Netherlands
    Clin Exp Metastasis 15:53-62. 1997
    ....
  25. ncbi Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease
    Marion E Meijer-Van Gelder
    Department of Medical Oncology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Cancer Res 64:4563-8. 2004
    ..Knowledge of their tumor expression levels might be helpful for future individualized therapy protocols, including possible new-targeted therapies based on the interference in the urokinase system...
  26. pmc The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer
    K Nooter
    Department of Medical Oncology, University Hospital Rotterdam and Rotterdam Cancer Institute Daniel den Hoed Kliniek, The Netherlands
    Br J Cancer 76:486-93. 1997
    ..In primary breast cancer, MRP might be related to altered cell biological behaviour, including a more aggressive phenotype, and resistance to adjuvant systemic chemotherapy...
  27. ncbi Insulin-like growth factor 1 (IGF-1) and urokinase-type plasminogen activator (uPA) are inversely related in human breast fibroblasts
    A M Sieuwerts
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital Rotterdam, The Netherlands
    Mol Cell Endocrinol 154:179-85. 1999
    ..These data suggest that in human breast fibroblasts IGF-1 controls the expression of uPA and that, possibly due to an altered sensitivity to uPA, tumor-associated fibroblasts have escaped this local control mechanism...
  28. ncbi Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer
    J G Klijn
    Division of Endocrine Oncology, Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, Groene Hilledijk 301, 3075 EA and University Hospital, Rotterdam, The Netherlands
    Steroids 65:825-30. 2000
    ..The clinical development of onapristone was stopped because of liver toxicity. At the present time, apart from development of new pure potent PAs, clinical investigation of combined therapy of PAs with antiestrogens are urgently needed...
  29. ncbi Tamoxifen resistance in breast cancer: elucidating mechanisms
    L C Dorssers
    Department of Pathology, Josephine Nefkens Institute, University Hospital Rotterdam, The Netherlands
    Drugs 61:1721-33. 2001
    ....
  30. ncbi Urokinase-type-plasminogen-activator (uPA) production by human breast (myo) fibroblasts in vitro: influence of transforming growth factor-beta(1) (TGF beta(1)) compared with factor(s) released by human epithelial-carcinoma cells
    A M Sieuwerts
    Medical Oncology Department Division of Endocrine Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek Academic Hospital Rotterdam, The Netherlands
    Int J Cancer 76:829-35. 1998
    ....
  31. ncbi Prognostic value of TP53 protein accumulation in human primary breast cancer: an analysis by luminometric immunoassay on 1491 tumor cytosols
    E M Berns
    Division of Endocrine Oncology Department of Medical Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Anticancer Res 17:3003-6. 1997
    ....
  32. ncbi Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts
    Anieta M Sieuwerts
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Thromb Haemost 87:674-83. 2002
    ....
  33. ncbi Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
    Maxime P Look
    Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 94:116-28. 2002
    ....
  34. ncbi RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response
    Herman Burger
    Department of Medical Oncology, Erasmus Medical Center Rotterdam Daniel den Hoed Kliniek Josephine Nefkens Institute, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:827-36. 2003
    ..The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in advanced disease...
  35. ncbi Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma
    Lucienne Speleman
    Department of Otolaryngology Head and Neck Surgery, Erasmus MC Daniel den Hoed, Rotterdam, The Netherlands
    Head Neck 29:341-50. 2007
    ..In this study, the prognostic importance of these factors in patients with primary head and neck squamous cell carcinoma (HNSCC) was evaluated and correlated with clinicopathologic variables...
  36. pmc Molecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological features
    E M Berns
    Division of Endocrine Oncology, Department of Medical Oncology, Rotterdam Cancer Center Daniel den Hoed Kliniek and University Hospital Rotterdam, The Netherlands
    Br J Cancer 85:538-45. 2001
    ..Furthermore this pilot analysis revealed a gene cluster that differentially expressed genes related to cell substrate formation, adhesion, migration and cell organization in BRCA1-mutated tumours compared to sporadic breast tumours...
  37. pmc Effects of suramin on cell-cycle kinetics of MCF-7 human breast cancer cells in vitro
    J A Foekens
    Department of Medical Oncology, Dr Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Br J Cancer 67:232-6. 1993
    ....
  38. ncbi Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Clin Cancer Res 12:3319-28. 2006
    ..To evaluate the prognostic value of cyclin E with a quantitative method for lymph node-negative primary breast cancer patients...
  39. ncbi Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer
    Els M J J Berns
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, 3000 DR Rotterdam, The Netherlands
    Clin Cancer Res 9:1253-8. 2003
    ..Mutant TP53 may up-regulate VEGF, whereas, on the other hand, wild-type TP53 may decrease VEGF production...
  40. doi Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics
    W Onstenk
    Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
    Cancer Treat Rev 39:691-700. 2013
    ..Here, we review these clinical studies. The various techniques used to interrogate CTCs are briefly described and an overview of the clinical relevance of CTC characterization in breast cancer is given...
  41. doi A new approach for rapid and reliable enumeration of circulating endothelial cells in patients
    J Kraan
    Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, Netherlands
    J Thromb Haemost 10:931-9. 2012
    ..Mature circulating endothelial cells (CECs) are surrogate markers of endothelial damage/dysfunction. A lack of standardized assays and consensus on CEC phenotype has resulted in a wide variation of reported CEC numbers (4-1300 per mL)...
  42. ncbi Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1
    Buddy Setyono-Han
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, 3000 DR Rotterdam, The Netherlands
    Thromb Haemost 93:779-86. 2005
    ..In conclusion, our results provide evidence that WX-UK1 as a single agent inhibits breast tumour growth and metastasis in vivo, and thus is a promising candidate drug to treat human cancer...
  43. ncbi How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Cancer Res 11:7311-21. 2005
    ..To evaluate the predictive value of the disintegrin and metalloproteinases, ADAM-9, ADAM-10, ADAM-11, and ADAM-12, and of the matrix metalloproteinases, MMP-2 and MMP-9, in patients with recurrent breast cancer treated with tamoxifen...
  44. ncbi Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer
    John A Foekens
    Department of Medical Oncology, Erasmus Medical Center, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 24:1665-71. 2006
    ..The aim of this study was to validate this gene signature in an independent more diverse population of LNN patients from multiple institutions...
  45. ncbi HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 25:662-8. 2007
    ..However, this ratio may predict a tumor's response to tamoxifen, its intrinsic aggressiveness, or both...
  46. ncbi Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer
    Anieta M Sieuwerts
    Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
    Clin Chem 53:1280-8. 2007
    ..TIMP-1 protein is a prognostic factor for recurrence-free and overall survival (OS) time in breast cancer. We evaluated the prognostic value of TIMP1 mRNA and a novel TIMP1 mRNA splice variant in 1301 primary breast cancer patients...
  47. doi Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:263-71. 2009
    ..The aim of this study was to evaluate SIAH2 for its (a) predictive/prognostic value, and (b) functional role in endocrine therapy resistance...
  48. doi Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute and Cancer Genomics Centre, Erasmus MC, Room BE 400, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    Breast Cancer Res Treat 118:455-68. 2009
    ..Our method allows molecular characterization specific for as little as one CTC, and can be used to expand the understanding of the biology of metastasis and, potentially, to improve patient management...
  49. doi Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus, The Netherlands
    Breast Cancer Res Treat 121:53-64. 2010
    ....
  50. doi Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response
    Jozien Helleman
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    Clin Cancer Res 14:5555-64. 2008
    ....
  51. pmc Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells
    Anieta M Sieuwerts
    Department of Medical Oncology, Josephine Nefkens Institute, Cancer Genomics Centre, Rotterdam, The Netherlands
    J Natl Cancer Inst 101:61-6. 2009
    ..New tests that include antibodies that specifically recognize normal-like breast tumor cells but not cells of hematopoietic origin are needed...
  52. ncbi Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer
    Bianca Mostert
    Department of Medical Oncology, Erasmus Medical Center Josephine Nefkens Institute and Cancer Genomics Centre, 3015 GE Rotterdam, The Netherlands
    Cancer Treat Rev 35:463-74. 2009
    ..We have focused on breast cancer as most clinical studies on CTC detection so far have been done in these patients...
  53. ncbi Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer
    John W M Martens
    Department of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Cancer Res 65:4101-17. 2005
    ..Concluding, our work indicates that promoter hypermethylation and mRNA expression of PSAT1 are indicators of response to tamoxifen-based endocrine therapy in steroid hormone receptor-positive patients with recurrent breast cancer...
  54. ncbi The use of genomic tools for the molecular understanding of breast cancer and to guide personalized medicine
    John A Foekens
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, Josephine Nefkens Institute and Cancer Genomics Centre, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands
    Drug Discov Today 13:481-7. 2008
    ..Here, we provide a short overview of the recent, promising developments in the field with emphasis on breast cancer...
  55. doi CHEK2 1100delC and male breast cancer in the Netherlands
    Marijke Wasielewski
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, CA, Rotterdam, The Netherlands
    Breast Cancer Res Treat 116:397-400. 2009
    ..1% Dutch population frequency assessed in 1,692 individuals (P = 0.05, OR = 4.1, 95% CI 1.2-14.3). Our data suggest that, in the Netherlands, CHEK2 1100delC is associated with an increased risk for MBC...
  56. doi Subtypes of breast cancer show preferential site of relapse
    Marcel Smid
    Department of Medical Oncology, Erasmus MC, Josephine Nefkens Institute, Rotterdam, The Netherlands
    Cancer Res 68:3108-14. 2008
    ..The five major molecular subtypes in breast cancer are evidently different with regard to their ability to metastasize to distant organ(s), and share biological features and pathways with their preferred distant metastatic site...
  57. doi High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS
    Arzu Umar
    University Medical Center Rotterdam, Josephine Nefkens Institute, Laboratory of Genomics and Proteomics in Breast Cancer, Department of Medical Oncology, Dr Molewaterplein 50, Be 430c, PO Box 2040, 3000 CA, Rotterdam, The Netherlands
    Expert Rev Proteomics 5:445-55. 2008
    ..In this review, we describe the applicability of FTICR-MS for breast cancer proteomics, particularly for the analysis of complex protein mixtures obtained from a limited number of cells typically available from clinical specimens...
  58. ncbi Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
    Maurice P H M Jansen
    Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Clin Oncol 23:732-40. 2005
    ..To discover a set of markers predictive for the type of response to endocrine therapy with the antiestrogen tamoxifen using gene expression profiling...
  59. pmc Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
    John A Foekens
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute, 3000 CA Rotterdam, The Netherlands
    Proc Natl Acad Sci U S A 105:13021-6. 2008
    ..In conclusion, our work connects four miRNAs to breast cancer progression and to several distinct biological processes involved therein...
  60. ncbi Circulating tumour cell detection on its way to routine diagnostic implementation?
    Stefan Sleijfer
    Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Clinic, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Eur J Cancer 43:2645-50. 2007
    ..This review addresses CTCs, and in particular, technical issues concerning their detection, clinical results obtained so far, and future perspectives...
  61. ncbi Genes associated with breast cancer metastatic to bone
    Marcel Smid
    Department of Medical Oncology, Erasmus MC Daniel den Hoed, Rotterdam, The Netherlands
    J Clin Oncol 24:2261-7. 2006
    ..The biology of tumors relapsing to bone is poorly understood. In this study, we initiated a search for genes that are implicated in tumors relapsing to bone in breast cancer...
  62. ncbi Four human breast cancer cell lines with biallelic inactivating alpha-catenin gene mutations
    Antoinette Hollestelle
    Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res Treat 122:125-33. 2010
    ..Together, our observations suggest that alpha-catenin may be a new tumor suppressor gene that operates in the E-cadherin tumor suppressor pathway...
  63. ncbi NanoLC-FT-ICR MS improves proteome coverage attainable for approximately 3000 laser-microdissected breast carcinoma cells
    Arzu Umar
    Department of Medical Oncology, Erasmus Medical Center Rotterdam, Josephine Nefkens Institute, The Netherlands
    Proteomics 7:323-9. 2007
    ..This work demonstrates that a substantial number of proteins can be detected and identified from limited number of cells using the AMT tag approach, and opens doors for high-throughput in-depth proteomics analysis of clinical samples...
  64. ncbi Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer
    Danielle Meijer
    Department of Pathology, Josephine Nefkens Institute, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
    Endocr Relat Cancer 15:101-11. 2008
    ..In addition, as altered expression of FGF17 causes tamoxifen resistance in vitro, the FGF signaling pathway could be a valuable target in the treatment of breast cancer patients resistant to endocrine treatment...
  65. ncbi Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  66. doi Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer
    Gert G Van den Eynden
    Translational Cancer Research Group Lab Pathology University of Antwerp University Hospital Antwerp, Wilrijk, Belgium
    Clin Cancer Res 14:2944-52. 2008
    ..Little is known about the molecular pathways involved...
  67. ncbi DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients
    Inko Nimmrich
    Department of Biomedical Research and Development and Technology Development, Epigenomics AG, Berlin, Germany
    Breast Cancer Res Treat 111:429-37. 2008
    ..In addition, we studied the association between PITX2 DNA methylation and PITX2 gene expression...
  68. ncbi Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University, D 81675 Munich, Germany
    Cancer Res 62:4617-22. 2002
    ....
  69. ncbi Aging of stromal-derived human breast fibroblasts might contribute to breast cancer progression
    John W M Martens
    Dept of Medical Oncology, Erasmus MC, Rotterdam, The Netherlands
    Thromb Haemost 89:393-404. 2003
    ..These age-induced levels of PAI-1, FGF-1, uPA and MMP-2 in stromal breast fibroblast could contribute to breast cancer progression...
  70. doi Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
    Carey K Anders
    Duke University Medical Center, Box 3841, 3829 Duke South, Red Zone, Durham, NC 27710, USA
    J Clin Oncol 26:3324-30. 2008
    ..Breast cancer arising in young women is correlated with inferior survival and higher incidence of negative clinicopathologic features. The biology driving this aggressive disease has yet to be defined...
  71. ncbi Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer
    Anne Sofie Schrohl
    The Finsen Laboratory, Rigshospitalet dept 8621, Strandboulevarden 49, DK 2100 Copenhagen, Denmark
    Mol Cell Proteomics 2:164-72. 2003
    ..Furthermore TIMP-1 adds prognostic information to that obtained from PAI-1. However, further validation in independent data sets is needed...
  72. ncbi Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer
    Anne Sofie Schrohl
    The Royal Veterinary and Agricultural University, Department of Pharmacology and Pathobiology, Frederiksberg C, Denmark
    Clin Cancer Res 10:2289-98. 2004
    ....
  73. ncbi Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients
    Peggy Manders
    Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Clin Cancer Res 9:6363-70. 2003
    ..We investigated the association between VEGF levels in tumor tissue and the effect of radiotherapy for relapse-free survival (RFS) and overall survival (OS) in node-negative breast cancer...
  74. ncbi Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer
    Nadia Harbeck
    Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Clin Breast Cancer 5:348-52. 2004
    ....
  75. ncbi Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer
    Anne Sofie Schrohl
    Department of Veterinary Pathobiology, The Royal Veterinary and Agricultural University, Frederiksberg C, Denmark
    Clin Cancer Res 12:7054-8. 2006
    ....
  76. ncbi Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer
    Peggy Manders
    Department of Chemical Endocrinology, University Medical Centre Nijmegen, Nijmegen, The Netherlands
    Cancer Res 64:659-64. 2004
    ..The results of this study imply that the expression of uPA:PAI-1 complex independently predicts the efficacy of adjuvant chemotherapy in patients with primary breast cancer...
  77. ncbi DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration wit
    Sabine Maier
    Department of Research, Epigenomics AG, Berlin, Germany
    Eur J Cancer 43:1679-86. 2007
    ..In addition, these low-risk postmenopausal patients seem to respond sufficiently well to tamoxifen so that they may not require up-front aromatase inhibitor therapy...
  78. ncbi Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time
    Paul N Span
    Department of Chemical Endocrinology, University Medical Center Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
    J Clin Oncol 22:691-8. 2004
    ..The tumor mRNA expression levels of mammaglobin, a novel breast-specific and breast cancer-associated marker, were correlated with disease outcome in 280 patients with primary breast cancer...
  79. pmc GnRH and LHR gene variants predict adverse outcome in premenopausal breast cancer patients
    Djura Piersma
    Department of Internal Medicine, Erasmus MC, 3000 CA Rotterdam, The Netherlands
    Breast Cancer Res 9:R51. 2007
    ..Breast cancer development and progression are dependent on estrogen activity. In premenopausal women, estrogen production is mainly regulated through the hypothalamic-pituitary-gonadal (HPG) axis...
  80. ncbi The prognostic value of BCAR1 in patients with primary breast cancer
    Lambert C J Dorssers
    Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam
    Clin Cancer Res 10:6194-202. 2004
    ..Here, we study the prognostic value of quantitative BCAR1 levels in a large series of breast cancer specimens...
  81. ncbi Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer
    Lambert C J Dorssers
    Department of Pathology, Division of Molecular Biology, Erasmus MC Rotterdam, Rotterdam, The Netherlands
    Clin Chem 50:1445-7. 2004
  82. ncbi Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue
    Nicolai Grebenchtchikov
    Department of Chemical Endocrinology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Clin Chem 50:1356-63. 2004
    ..The aim of the present study was to develop an ELISA to measure BCAR1 quantitatively in extracts of human breast cancer tissue...
  83. ncbi Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry
    Arzu Umar
    Department of Neurology and Center for Biomics, Erasmus MC, Rotterdam, The Netherlands
    Proteomics 5:2680-8. 2005
    ..In conclusion, we describe a method that is suitable for direct peptide profiling on small amounts of microdissected cells obtained from breast cancer tissues...
  84. ncbi Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and T
    Manfred Schmitt
    Clinical Research Unit, Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technische Universitaet Muenchen, Ismaninger Strasse 22, D 81675 Munich, Germany
    Int J Oncol 25:1397-406. 2004
    ..With this approach, a major step forward in the knowledge and understanding of the biological role and the clinical utility of tumor-associated biomarkers would be anticipated...
  85. ncbi Re: Limits of predictive models using microarray data for breast cancer clinical treatment outcome
    Maurice P H M Jansen
    J Natl Cancer Inst 97:1851-2; author reply 1852-3. 2005
  86. ncbi Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ....
  87. ncbi Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?
    Paul N Span
    Department of Chemical Endocrinology, RAdboud University of Nimegen Medical Centre, Nijmegen, The Netherlands
    Clin Chem 52:1693-700. 2006
    ..In this study, we assessed whether the survivin splice variants modulate or add to the prognostic value of total survivin in breast cancer...
  88. ncbi European Organisation for Research and Treatment of Cancer (EORTC) Pathobiology Group standard operating procedure for the preparation of human tumour tissue extracts suited for the quantitative analysis of tissue-associated biomarkers
    Manfred Schmitt
    Clinical Research Unit, Department of Obstetrics and Gynecology, Technical University of Munich, Germany
    Eur J Cancer 43:835-44. 2007
    ..The resulting tissue cell debris sediment is a rich source of genomic DNA...
  89. ncbi Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties
    Jurgen Joossens
    Laboratory of Medicinal Chemistry, University of Antwerp, Universiteitsplein 1, B 2610 Antwerp, Belgium
    J Med Chem 50:6638-46. 2007
    ..We report in this paper a preclinical proof of concept that selective, irreversible uPA inhibitors could be valuable in antimetastatic therapy...
  90. pmc Age-specific differences in oncogenic pathway deregulation seen in human breast tumors
    Carey K Anders
    Division of Medical Oncology, Department of Medicine, Duke University, Durham, North Carolina, USA
    PLoS ONE 3:e1373. 2008
    ..To define the biology driving the aggressive nature of breast cancer arising in young women...
  91. ncbi Urokinase receptor splice variant uPAR-del4/5-associated gene expression in breast cancer: identification of rab31 as an independent prognostic factor
    Matthias Kotzsch
    Institute of Pathology, Dresden University of Technology, Fetscherstr 74, 01307, Dresden, Germany
    Breast Cancer Res Treat 111:229-40. 2008
    ..To evaluate the pure prognostic impact of the uPA-receptor splice variant uPAR-del4/5 for lymph node-negative breast cancer patients, and to identify differentially expressed genes associated with high or low uPAR-del4/5 mRNA levels...
  92. doi Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics
    Patrizia Sini
    Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland
    Cancer Res 68:1581-92. 2008
    ....
  93. pmc Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer
    Jack X Yu
    Veridex LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    BMC Cancer 7:182. 2007
    ..Published prognostic gene signatures in breast cancer have few genes in common. Here we provide a rationale for this observation by studying the prognostic power and the underlying biological pathways of different gene signatures...
  94. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
    ..Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings...
  95. pmc Lung metastasis genes couple breast tumor size and metastatic spread
    Andy J Minn
    Department of Radiation and Cellular Oncology, Center for Molecular Oncology, and Ludwig Center for Metastasis Research, University of Chicago, Chicago, IL 60637, USA
    Proc Natl Acad Sci U S A 104:6740-5. 2007
    ....
  96. ncbi Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
    ..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed...
  97. ncbi Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer
    Selina Raguz
    Medical Research Council Clinical Sciences Centre, Imperial College Faculty of Medicine, Hammersmith Hospital Campus, London, United Kingdom
    Int J Cancer 122:1058-67. 2008
    ....